Watson Pharmaceuticals Announces New Research Showing Rapalfo (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome - Drugs.com MedNews
Links shared publicly online about this topic.
- 284total visits
Watson Pharmaceuticals Announces New Research Showing Rapalfo (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome - Drugs.com MedNews
- Treatment Reduces Symptoms and Improves Quality of Life - - RAPAFLO(R) demonstrated significant response in men with moderate to severe CP CPPS - New data pre
View full resource at drugs.com
Tags: Pain, Benign Prostatic Hypertrophy Medication, Disease and Condition, Drug, Pharma, Rapaflo, Watson Pharmaceuticals
Most Recently Shared on May 18, 2011 at 2:13 pm By:
Watson Pharmaceuticals Announces New Research Showing Rapalfo (silodosin) Improves Outcomes for Chronic Pr... http://bit.ly/jMxya5 #drug
Advertisement
